Avadel Pharmaceuticals (AVDL): רווח נקי למניה ב-12 החודשים האחרונים
Net income per share over 12 months demonstrates the asset's dynamics, where the -0.01 level captures recent values for Avadel Pharmaceuticals (AVDL). A neutral geopolitical backdrop and the humanitarian status of the therapy support exchange rate stability. Market share growth is driven by the convenience of administering the Lumryz drug. High margins with a small workforce are achieved through a patented extended-release formula.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_AVDL_-_Avadel-Pharmaceuticals_-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) Avadel Pharmaceuticals (AVDL): לתקופה 04.07.2022 - 28.02.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Avadel Pharma (AVDL)
The selection of high-quality issuers is based on an analysis of specific yield, where the trailing 12-month EPS reflects the net profit allocated per share per year. For Avadel Pharmaceuticals (AVDL), this metric verifies the efficiency of cost management regarding ESG optimization of supply chains and bioethical drug development, allowing investors to assess the real profitability of the business through the dynamics of this chart.
